Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: Systematic review and meta-analysis of randomized controlled trials

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Xu, A Man ^a   Huang, Lei ^a   Liu, Wei ^b   Gao, Shuang ^a   Han, Wen Xiu ^a   Wei, Zhi Jian ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; LYMPH NODE METASTASIS; META ANALYSIS; POSTOPERATIVE COMPLICATION; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; ADENOCARCINOMA; ADJUVANT THERAPY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; MORTALITY; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ADENOCARCINOMA; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; HUMANS; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84900420453     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086941     Document Type: Review

References (80)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
4. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
5. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, et al. (2009) EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 45: 931-991.
6. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, et al. (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725-730.
7. Okines A, Verheij M, Allum W, Cunningham D, Cervantes A, et al. (2010) Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 Suppl 5: v50-54.
8. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, et al. (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29: 1715-1721.
9. Yoshikawa T, Sasako M (2012) Gastrointestinal cancer: Adjuvant chemotherapy after D2 gastrectomy for gastric cancer. Nat Rev Clin Oncol 9: 192-194.
10. Japanese Gastric Cancer A (2011) Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 14: 113-123.
11. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, et al. (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379: 315-321.
12. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, et al. (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29: 4387-4393.
13. Group G, Paoletti X, Oba K, Burzykowski T, Michiels S, et al. (2010) Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 303: 1729-1737.
14. Wilke H, Preusser P, Fink U, Gunzer U, Meyer HJ, et al. (1989) Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 7: 1318-1326. (Pubitemid 19220135)
15. Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, et al. (2009) Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg 96: 1015-1022.
16. Kinoshita T, Sasako M, Sano T, Katai H, Furukawa H, et al. (2009) Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002). Gastric Cancer 12: 37-42.
17. Liao Y, Yang ZL, Peng JS, Xiang J, Wang JP (2013) Neoadjuvant chemotherapy for gastric cancer: a meta-analysis of randomized, controlled trials. J Gastroenterol Hepatol 28: 777-782.
18. Ge L, Wang HJ, Yin D, Lei C, Zhu JF, et al. (2012) Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis. World J Gastroenterol 18: 7384-7393.
19. Li W, Qin J, Sun YH, Liu TS (2010) Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol 16: 5621-5628.
20. Wu AW, Xu GW, Wang HY, Ji JF, Tang JL (2007) Neoadjuvant chemotherapy versus none for resectable gastric cancer. Cochrane Database Syst Rev: CD005047.
21. Yonemura Y, Sawa T, Kinoshita K, Matsuki N, Fushida S, et al. (1993) Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 17: 256-261; discussion 261-252.
22. Zhang CW, Zou SC, Shi D, Zhao DJ (2004) Clinical significance of preoperative regional intra-arterial infusion chemotherapy for advanced gastric cancer. World J Gastroenterol 10: 3070-3072. (Pubitemid 39303067)
23. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20.
24. Lygidakis NJ, Sgourakis G, Aphinives P (1999) Upper abdominal stop-flow perfusion as a neo and adjuvant hypoxic regional chemotherapy for resectable gastric carcinoma. A prospective randomized clinical trial. Hepatogastroenterology 46: 2035-2038. (Pubitemid 29366394)
25. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008-2012. (Pubitemid 30214957)
26. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P(2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535.
27. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339: b2700.
28. Japanese Gastric Cancer A (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14: 101-112.
29. Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, et al. (2011) Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res 17: 2693-2701.
30. Chau I, Norman AR, Cunningham D, Oates J, Hawkins R, et al. (2009) The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma-individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol 20: 885-891.
31. Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5: 13.
32. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12. (Pubitemid 26120810)
33. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, et al. (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352: 609-613. (Pubitemid 28380142)
34. Clarke M, Horton R (2001) Bringing it all together: Lancet-Cochrane collaborate on systematic reviews. Lancet 357: 1728. (Pubitemid 32524199)
35. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558. (Pubitemid 34746062)
36. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560. (Pubitemid 37088507)
37. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. (Pubitemid 17189972)
38. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. (Pubitemid 27387172)
39. Macaskill P, Walter SD, Irwig L (2001) A comparison of methods to detect publication bias in meta-analysis. Stat Med 20: 641-654. (Pubitemid 32166424)
40. Fisher DJ, Copas AJ, Tierney JF, Parmar MK (2011) A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners. J Clin Epidemiol 64: 949-967.
41. Shchepotin I, Evans S, Chorny V, Ugrinov O, Osinsky S, et al. (1995) Preoperative superselective intraarterial chemotherapy in the combined treatment of gastric-carcinoma. Oncol Rep 2: 473-479.
42. Kang YK, Choi DW, Im YH, Kim CM, Lee JI, et al. (1996) A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer. Abstract 503 presented at the ASCO Annual Meeting. ASCO website. Available: URL: http://www.asco.org/ASCOv2/ Meetings/Abstracts?&vmview=abst-detail-view&confID=29&abstractID= 10042. Accessed 2013 July 26.
43. Kobayashi T, Kimura T (2000) Long-term outcome of preoperative chemotherapy with 59-deoxy-5-fluorouridine (59-DFUR) for gastric cancer. Gan To Kagaku Ryoho 27: 1521-1526.
44. Wang XL, Wu GX, Zhang MD, Guo M, Zhang H, et al. (2000) A favorable impact of preoperative FPLC chemotherapy on patients with gastric cardia cancer. Oncol Rep 7: 241-244.
45. Hartgrink HH, van de Velde CJ, Putter H, Songun I, Tesselaar ME, et al. (2004) Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 30: 643-649. (Pubitemid 39060735)
46. Nio Y, Koike M, Omori H, Hashimoto K, Itakura M, et al. (2004) A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer-a single institute study. Anticancer Res 24: 1879-1887. (Pubitemid 38954602)
47. Zhao WH, Wang SF, Ding W, Sheng JM, Ma ZM, et al. (2006) Apoptosis induced by preoperative oral 5′-DFUR administration in gastric adenocarcinoma and its mechanism of action. World J Gastroenterol 12: 1356-1361.
48. Imano M, Itoh T, Satou T, Sogo Y, Hirai H, et al. (2010) Prospective randomized trial of short-term neoadjuvant chemotherapy for advanced gastric cancer. Eur J Surg Oncol 36: 963-968.
49. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, et al. (2010) Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 28: 5210-5218.
50. Menges M, Hoehler T (2009) Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction. J Cancer Res Clin Oncol 135: 29-38.
51. Ott K, Lordick F, Blank S, Buchler M (2011) Gastric cancer: surgery in 2011. Langenbecks Arch Surg 396: 743-758.
52. Kodera Y, Ito S, Mochizuki Y, Ohashi N, Tanaka C, et al. (2012) Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study. Gastric Cancer 15: 335-337.
53. Takahari D, Hamaguchi T, Yoshimura K, Katai H, Ito S, et al. (2011) Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol 67: 1423-1428.
54. Kodera Y, Ishiyama A, Yoshikawa T, Kinoshita T, Ito S, et al. (2010) A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703). Gastric Cancer 13: 197-203.
55. Inoue K, Nakane Y, Kogire M, Fujitani K, Kimura Y, et al. (2012) Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer. Eur J Surg Oncol 38: 143-149.
56. Nashimoto A, Yabusaki H, Nakagawa S, Takii Y, Tsuchiya Y, et al. (2009) Preoperative chemotherapy with S-1 and cisplatin for highly advanced gastric cancer. Anticancer Res 29: 4689-4696.
57. Yoshikawa T, Omura K, Kobayashi O, Nashimoto A, Takabayashi A, et al. (2010) A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study). Eur J Surg Oncol 36: 546-551.
58. Sakamoto J, Matsui T, Kodera Y (2009) Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer 12: 69-78.
59. Nishikawa K, Morita S, Matsui T, Kobayashi M, Takeuchi Y, et al. (2012) A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer. Gastric Cancer 15: 363-369.
60. Tsuburaya A, Nagata N, Cho H, Hirabayashi N, Kobayashi M, et al. (2013) Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer. Cancer Chemother Pharmacol 71: 1309-1314.
61. Bolke E, Peiper M, Knoefel WT, Baldus SE, Schauer M, et al. (2011) Multimodal therapy in locally advanced gastric cancer. Dtsch Med Wochenschr 136: 2205-2211.
62. Untch M, von Minckwitz G (2009) Recent advances in systemic therapy: advances in neoadjuvant (primary) systemic therapy with cytotoxic agents. Breast Cancer Res 11: 203.
63. Li Q, Jiang Y, Wei W, Yang H, Liu J (2013) Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS One 8: e53403.
64. Chen MB, Wu XY, Yu R, Li C, Wang LQ, et al. (2012) P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer. PLoS One 7: e45388.
65. Chen MB, Zhu YQ, Xu JY, Wang LQ, Liu CY, et al. (2012) Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. PLoS One 7: e39655.
66. Wu AW, Ji JF (2012) Neoadjuvant chemotherapy for locally advanced gastric cancer: With or without radiation. World J Gastrointest Surg 4: 27-31.
67. Wang LB, Teng RY, Jiang ZN, Hu WX, Dong MJ, et al. (2012) Clinicopathologic variables predicting tumor response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer. J Surg Oncol 105: 293-296.
68. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, et al. (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15: 261-267. (Pubitemid 27020582)
69. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, et al. (2010) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev: CD004064.
70. Hasegawa S, Yoshikawa T, Shirai J, Fujikawa H, Cho H, et al. (2013) A prospective validation study to diagnose serosal invasion and nodal metastases of gastric cancer by multidetector-row CT. Ann Surg Oncol 20: 2016-2022.
71. Misra S, Pedroso FE, DiPasco PJ, Solomon NL, Gennis E, et al. (2012) Does neoadjuvant chemotherapy improve outcomes for patients with gastric cancer? J Surg Res 178: 623-631.
72. Iwase H, Shimada M, Tsuzuki T, Ina K, Sugihara M, et al. (2011) A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer. Oncology 80: 76-83.
73. Kim JY, Do YR, Park KU, Kim JG, Chae YS, et al. (2011) Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 67: 527-532.
74. Sato Y, Takayama T, Sagawa T, Takahashi Y, Ohnuma H, et al. (2010) Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol 66: 721-728.
75. Koizumi W, Nakayama N, Tanabe S, Sasaki T, Higuchi K, et al. (2012) A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemother Pharmacol 69: 407-413.
76. Nishiyama M, Wada S (2009) Docetaxel: its role in current and future treatments for advanced gastric cancer. Gastric Cancer 12: 132-141.
77. Yoshikawa T, Tsuburaya A, Morita S, Kodera Y, Ito S, et al. (2010) A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS). Jpn J Clin Oncol 40: 369-372.
78. Fushida S, Nashimoto A, Fukushima N, Kawachi Y, Fujimura T, et al. (2012) Phase II trial of preoperative chemotherapy with docetaxel, cisplatin and S-1 for T4 locally advanced gastric cancer. Jpn J Clin Oncol 42: 131-133.
79. Biffi R, Fazio N, Luca F, Chiappa A, Andreoni B, et al. (2010) Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World J Gastroenterol 16: 868-874.
80. Dikken JL, van Sandick JW, Maurits Swellengrebel HA, Lind PA, Putter H, et al. (2011) Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer 11: 329.